Hysterosalpingography and Hysteroscopy in ICSI

February 27, 2021 updated by: Aljazeera Hospital

Hysterosalpingography and Hysteroscopy in Intracytoplasmic Sperm Injection

unexplained infertility is a rising problem in clinical practice

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Assessment of uterine cavity is very important before ICSI

Study Type

Interventional

Enrollment (Anticipated)

200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Giza, Egypt
        • Aljazeera( Al Gazeera) hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 38 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • women with infertility

Exclusion Criteria:

  • women with medical disorders

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: tubal occlusion
occlusion of tubes
Other: occlusion of tubes
to occlude the fallopian tubes
Sham Comparator: non occlusion of tube
non occlusion of tubes
Other: non occlusion of tubes
not to occlude the tubes

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the number of women who will become pregnant
Time Frame: 3 months
number of women who will have positive pregnancy test
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Aljazeera Hospital

Investigators

  • Principal Investigator: Mahmoud Alalfy, Algezeera hospitaland National Research Centre ,Egypt

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

March 2, 2021

Primary Completion (Anticipated)

February 1, 2022

Study Completion (Anticipated)

February 15, 2022

Study Registration Dates

First Submitted

February 27, 2021

First Submitted That Met QC Criteria

February 27, 2021

First Posted (Actual)

March 3, 2021

Study Record Updates

Last Update Posted (Actual)

March 3, 2021

Last Update Submitted That Met QC Criteria

February 27, 2021

Last Verified

February 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • tubal disease

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe